Leo International Precision Health (LIPH) is an integrated, AI-driven precision health investment platform. The recent acquisition of our first six portfolio companies now includes amiko AI, a Taiwan-based AI-technology company.
By integrating amiko’s advanced AI capabilities, LIPH further strengthens its precision health ecosystem, enhancing data-driven insights, accelerating innovation across diagnostics and therapeutics, and enabling more personalized healthcare outcomes.
amiko AI is developing a human–AI collaborative scientific platform designed to speed up molecular drug design and translational research. Its proprietary technology stack combines an AI Co-Scientist for hypothesis generation supporting drug discovery, including drug repurposing and novel target discovery, a modular ToolUniverse enabling autonomous molecular design workflows, and an ontology-based biomedical knowledge layer to enhance reasoning and transparency.
The result: scalable AI-assisted biomedical R&D with reduced discovery time and cost, advancing the next generation of precision health applications.
Find out more about LIPH: www.liphag.com
Find out more about amiko AI: https://amiko.net/
